Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 6 (2009), Issue 6 (June)

1. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
   Cancer Chemother Pharmacol, 64(2): 361-9. [Abstract] [Full-text]
2. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
   Target Oncol, 4(2): 77-88. [Abstract] [Full-text]
3. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model.
   Breast Cancer Res, 11(3): R25. [Abstract] [Full-text]
4. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
   Lancet Oncol, 10(6): 581-8. [Abstract] [Full-text]
5. Breast cancer and pregnancy: how safe is trastuzumab?
   Nat Rev Clin Oncol, 6(6): 367-70. [Abstract] [Full-text]
6. Multicolor in vivo targeted imaging to guide real-time surgery of HER2-positive micrometastases in a two-tumor coincident model of ovarian cancer.
   Cancer Sci, 100(6): 1099-104. [Abstract] [Full-text]
7. Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel.
   Nanomed, 4(4): 431-45. [Abstract] [Full-text]
8. Neoadjuvant chemotherapy for "Triple Negative" breast cancer: a review of current practice and future outlook.
   Med Oncol. [Abstract] [Full-text]
9. Induction of ERBB2 nuclear transport after radiation in breast cancer cells.
   J Huazhong Univ Sci Technolog Med Sci, 29(3): 350-3. [Abstract] [Full-text]
10. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.
    Mol Cancer Ther, 8(6): 1557-69. [Abstract] [Full-text]
11. Emerging drugs for esophageal cancer.
    Expert Opin Emerg Drugs, 14(2): 329-39. [Abstract] [Full-text]
12. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells.
    Biochem Biophys Res Commun, 385(3): 454-9. [Abstract] [Full-text]
13. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Clin Cancer Res, 15(12): 4147-56. [Abstract] [Full-text]
14. Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection.
    Bioconjug Chem, 20(6): 1228-36. [Abstract] [Full-text]
15. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
    J Clin Oncol, 27(18): 2962-9. [Abstract] [Full-text]
16. Novel investigational drugs for gastric cancer.
    Expert Opin Investig Drugs, 18(7): 945-55. [Abstract] [Full-text]
17. Molecular targets for treatment of inflammatory breast cancer.
    Nat Rev Clin Oncol, 6(7): 387-94. [Abstract] [Full-text]
18. Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma.
    Anal Biochem, 391(2): 114-20. [Abstract] [Full-text]
19. Radiosensitization of Chemotherapy-Refractory, Locally Advanced or Locally Recurrent Breast Cancer with Trastuzumab: A Phase II Trial.
    Int J Radiat Oncol Biol Phys. [Abstract] [Full-text]

© 2004-2010 Herceptin Research Today. All Rights Reserved.